✦ LIBER ✦

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

✍ Scribed by D.W. Miles; S.L. De Haas; G. Romieu; A. Chan; L. Dirix; J. Cortes; P.R. Delmar; S.J. Scherer

Book ID: 117661409
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 44 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70916-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5072 POSTER First-Line Bevacizumab (Bev)

5072 POSTER First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) in Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study

✍ Foerster, F.; Aktas, B.; Geberth, M.; Tschechne, B.; Schneeweiss, A.; Salat, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

455 A phase II study of first-line combi

455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC)

✍ F. Lenz; F. Beldermann; M. Geberth; G. Bastert; A. Schneeweiss 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

5058 Bevacizumab (Bev) combined with eit

5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

✍ I. Lang; M. Inbar; G. Steger; R. Greil; Z. Zvirbule; S. Beslija; Z. Kahán; V. Ta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

489 Bevacizumab (BV) in combination with

489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies

✍ J. Glaspy; V. Dieras; A. Brufsky; D.W. Miles; S.C. Phan; J. O'Shaughnessy 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB